Pancreatic Adenocarcinoma Clinical Trials

32 studies are recruiting for pancreatic adenocarcinoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Houston, Texas 12 New York, New York 11 Dallas, Texas 8 Los Angeles, California 8 Nashville, Tennessee 8 San Antonio, Texas 8 Phoenix, Arizona 7 Boston, Massachusetts 6 Chicago, Illinois 6 Fairfax, Virginia 6 Jacksonville, Florida 6 Rochester, Minnesota 6 Durham, North Carolina 5 Grand Rapids, Michigan 5 New Brunswick, New Jersey 5 Seattle, Washington 5 Baltimore, Maryland 4 Miami, Florida 4 Milwaukee, Wisconsin 4 Newport Beach, California 4 Philadelphia, Pennsylvania 4 Scottsdale, Arizona 4 Tampa, Florida 4 Atlanta, Georgia 3 Birmingham, Alabama 3 Chapel Hill, North Carolina 3 Cincinnati, Ohio 3 Columbus, Ohio 3 Detroit, Michigan 3 Duarte, California 3 East Brunswick, New Jersey 3 Hackensack, New Jersey 3 New Haven, Connecticut 3 Pittsburgh, Pennsylvania 3 Portland, Oregon 3 Sacramento, California 3 Santa Monica, California 3 West Valley City, Utah 3

Studies, page 2

  1. A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

    This is a single arm phase II study. All patients will receive 3 cycles of the treatment of nab-paclitaxel (Days 1, 8 and 15), gemcitabine (Days 1, 8 and 15), and TTFields (worn every day for at least 18 hours). Following the initial 3 cycles of gemcitabine/nab-paclitaxel/TTFields treatment, patien…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Run by
    Ashish Manne

    See if you can join NCT05624918 on ClinicalTrials.gov

  2. Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

    This phase I/II trial studies the side effects and best dose of panitumumab-IRDye800 and to see how well it works in finding cancer in patients with pancreatic cancer who are undergoing surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and IRDye800CW, an investigationa…

    Stage
    Phase 1
    Ages
    19 and older
    Site
    Stanford University, School of Medicine, Palo Alto, California
    Run by
    George Poultsides

    See if you can join NCT03384238 on ClinicalTrials.gov

  3. Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders

    RATIONALE: Gathering medical information and collecting and storing samples of blood and tissue to test in the laboratory may help doctors develop better ways to screen people at risk for pancreatic cancer or other pancreatic disorders in the future. PURPOSE: This clinical trial is collecting medic…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Mayo Clinic Hospital in Arizona, Phoenix, Arizona
    Locations
    3 in total
    Run by
    Mayo Clinic

    See if you can join NCT00830557 on ClinicalTrials.gov

  4. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    HonorHealth Research Institute, Scottsdale, Arizona
    Locations
    21 in total
    Run by
    Clasp Therapeutics, Inc.

    See if you can join NCT06778863 on ClinicalTrials.gov

  5. Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

    This study is a first in human Phase 1 study that involves patients with a type of cancer called HER2 (Human Epidermal Growth Factor Receptor 2) positive cancer. This study asks patients to volunteer to take part in a research study investigating the safety and efficacy of using special immune cell…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Baylor St. Luke's Medical Center, Houston, Texas
    Run by
    Baylor College of Medicine

    See if you can join NCT03740256 on ClinicalTrials.gov

  6. Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

    Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Louisville, Louisville, Kentucky
    Run by
    University of Louisville

    See if you can join NCT03080974 on ClinicalTrials.gov

  7. Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

    The purpose of the proposed study is to establish the safety of combining irinotecan chemotherapy with 5-FU, leucovorin/folinic acid, oxaliplatin, and docetaxel (abbreviated as the I-FLOAT study of gFOLFOXIRITAX) chemotherapies (leucovorin/folinic acid is a vitamin to make 5-FU work well).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The University of Chicago, Chicago, Illinois
    Run by
    University of Chicago

    See if you can join NCT04361708 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.